Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment TA1139 11 March 2026 11 March 2026 Durvalumab with gemcitabine and cisplatin for ...
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568] Technology appraisal guidance 10 June 2027 Tafasitamab with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results